Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597672 | 0.86 | SCN9A (1.00) | SCN9ATP53MAPTTHRBCHRM5 | |
| SCHEMBL4625797 | 0.83 | SCN9A (1.00) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL4595935 | 0.81 | SCN9A (1.00) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL4597208 | 0.81 | SCN9A (1.00) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL4595619 | 0.81 | SCN9A (1.00) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL4596924 | 0.80 | SCN9A (0.77) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL14533506 | 0.80 | SCN9A (0.81) | SCN9ATP53MAPTTHRBALDH1A1 | |
| SCHEMBL20988966 | 0.77 | SCN9A (0.83) | SCN9ATP53MAPTCHRM5 | |
| SCHEMBL4597668 | 0.76 | SCN9A (0.80) | SCN9ATP53MAPTTHRBCHRM5 | |
| SCHEMBL4596996 | 0.76 | SCN9A (1.00) | SCN9ATP53MAPTTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | claimed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | SCN9A 148/4885TP53 4519/4885MAPT 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.